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854Objectives: Fibrocytes are integral in the development of fibroproliferative disease after lung transplantation.
Undifferentiated fibrocytes (CD45þanti-collagen 1þCXCR4þ) preferentially traffic by way of the CXCR4/
CXCL12 axis and differentiate into smooth muscle actin-producing (CD45þCXCR4þa-smooth muscle actinþ)
cells. We postulated that an antibody directed against CXCL12 would attenuate fibrocyte migration and
fibro-obliteration of heterotopic tracheal transplant allografts.
Methods:A total alloantigenic mismatch murine heterotopic tracheal transplant model of obliterative bronchio-
litis was used. The mice were treated with either goat-anti-human CXCL12 F(ab0)2 or goat IgG F(ab0)2. Buffy
coat, bone marrow, and trachea allografts were collected and analyzed using flow cytometry. Tracheal luminal
obliteration was assessed using hematoxylin-eosin and Direct Red 80 collagen stain.
Results: Compared with the controls, the anti-CXCL12–treated mice showed a significant decrease in tracheal
allograft fibrocyte populations at 7 and 21 days after transplantation. Bone marrow and buffy coat aspirates
showed the same trend at 7 days. In the anti-CXCL12–treated mice, there was a 35% decrease in luminal oblit-
eration at 21 days (65% vs 100% obliterated; interquartile range, 38% vs 10%; P ¼ .010) and decreased
luminal collagen deposition at 21 and 28 days after transplantation (P ¼ .042 and P ¼ .012, respectively).
Conclusions: Understanding the role of fibrocytes in airway fibrosis after lung transplantation could lead to
a paradigm shift in treatment strategy. Anti-CXCL12 antibody afforded protection against infiltrating fibrocytes
and reduced the deterioration of the tracheal allografts. Thus, the CXCR4/CXCL12 axis is a novel target for the
treatment of fibro-obliteration after lung transplantation, and the quantification of fibrocyte populations could
provide clinicians with a biomarker of fibrosis, allowing individualized drug therapy. (J Thorac Cardiovasc
Surg 2013;145:854-61)Bronchiolitis obliterans syndrome (BOS) is a leading cause
of morbidity and mortality after lung transplantation.1 Lung
fibroblasts and myofibroblasts are critical for the develop-
ment of fibrosis and are thought to arise from 3 locations:
the resident proliferation of fibroblasts, epithelial to mesen-
chyme transition, and bone marrow-derived mesenchymal
progenitor cells, fibrocytes.2
Fibrocytes (CD45þanti-collagen 1 [Col1]þCXCR4þ) are
bone marrow-derived mesenchymal stem cells that are
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They travel to injured tissues by way of the CXCR4/
CXCL12 chemokine axis. Fibrocytes differentiate into
a-smooth muscle actin (a-SMAþ) producing fibroblasts/
myofibroblasts.2,3 Although fibrocytes have been shown
to respond to several chemokines and express CCR3,
CCR5, and CCR7 chemokines, the CXCR4/CXCL12
biologic axis is the predominate driving force for
fibrocyte trafficking after airway injury.4,5
Fibrocytes were first described in the context of normal
wound healing; however, their importance in the progres-
sion of fibrotic and asthmatic lung disease has since been
demonstrated.6 Patients with exacerbation of idiopathic pul-
monary fibrosis (IPF) have been shown to have an elevated
proportion of peripheral blood fibrocytes compared with pa-
tients with stable IPF. Furthermore, the total circulating
fibrocyte population in those with IPF was found to be an
independent predictor of death.7
In a prospective study aimed at quantifying circulating
fibrocyte populations (CD45þCol1þ) in patients after lung
transplantation, we found a statistically significant increase
in the circulating fibrocyte number in patients diagnosed
with BOS (defined according to the forced expiratoryery c March 2013
Abbreviations and Acronyms
a-SMA ¼ a-smooth muscle actin
BOS ¼ bronchiolitis obliterans syndrome
Col1 ¼ collagen 1
IPF ¼ idiopathic pulmonary fibrosis
mTOR ¼ mammalian target of rapamycin
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BOS (8.9 3 105 cells/mL vs 2.96 3 105 cells/mL, respec-
tively). Furthermore, we found significant incremental in-
creases in circulating fibrocyte numbers with advancing
BOS stage, suggesting a role for fibrocytes in BOS progres-
sion.8 This has been corroborated by another study, which
found a statistically significant increase in the number of fi-
brocytes on staining for CXCR4/prolyl 4-hydroxylase in
lung biopsy specimens from lung transplant patients with
BOS compared with controls.9
The associations between fibrocyte numbers and BOS
progression in human studies has suggested, but not yet
proved, that fibrocytes have detrimental effects in pulmo-
nary fibrosis. Given the correlation of fibrocyte number
and clinical BOS stage and the importance of the
CXCR4/CXCL12 axis in fibrocyte trafficking, we hypothe-
sized that immunotherapy directed against CXCL12 would
attenuate airway fibrosis and obliteration in a well-
established murine heterotopic tracheal transplant model
of obliterative bronchiolitis.10,11
METHODS
Generation and Purification of Anti-CXCL12 IgG
F(ab0)2 Fragments
Goat anti-human CXCL12 antibodies were purified using the Melon
Gel IgG purification Kit (Thermo Scientific, Rockford, Ill). Normal goat
IgG and purified goat anti-human CXCL12 IgG were digested with Immo-
bilized Pepsin (Pierce, Rockford, Ill). Fragments were recovered and dia-
lyzed against phosphate-buffered saline. F(ab0)2 were purified from Fc
fragments using NUNC Protein G columns (Nunc, Rockford, Ill).
Mice
All mice (Jackson Laboratory, Bar Harbor, Maine) received humane
care according to the ‘‘Principles of Laboratory Animal Care,’’ formulated
by the National Society for Medical Research and the ‘‘Guide for the Care
and Use of Laboratory Animals.’’ The Animal Care and Use Committee at
the University of Virginia approved the study protocol.
Experimental Group Design
We used a heterotopic subcutaneous tracheal transplant model of bron-
chiolitis obliterans, as previously described.11 A major histocompatability
complex class I and II mismatch was produced by transplanting 4 Balb/c
(H-2d) tracheas into 1 C57BL/6 (H-2b) recipient. Four donor trachea allo-
grafts were used per recipient to ensure adequate tracheal tissue for fibro-
cyte determination and histologic examination. The mice were divided into
2 groups: the IgG control group [intraperitoneal injections of normal goat
IgG F(ab0)2] and the anti-CXCL12 group [intraperitoneal injections of anti-
CXCL12 F(ab0)2]. Each group included 6 recipients for a total of 120The Journal of Thoracic and Cadonors and 30 recipients. Thus, there were a total of 240 donors and 60 re-
cipients. All recipients were given intraperitoneal injections at days1, 0,
and 1, and then every other day until the endpoints. The mice were killed,
and the allografts were collected on days 3, 7, 12, 21, or 28. Tracheal allo-
grafts from 5 of the 6 mice at each point were pooled for flow cytometry
analysis, and the tracheal allografts from the sixth mousewere used for his-
tologic examination and Sirius Red staining.
Fluorescence Activated Cell Sorter Analysis
Single cell suspensions isolated from bone marrow, peripheral blood,
and trachea allografts were stained with peridinin-chlorophyll-protein
complex–labeled CD45, phycoerythrin-labeled CXCR4 (BD Biosciences,
SanDiego, Calif), or isotype controls. Subsequently, the cells were permea-
bilized using cytofix/cytoperm for staining with DyLight-488 conjugated
anti-Col1, phycoerythrin-labeled a-SMA, or isotype controls. Anti-Col1
and a rabbit IgG isotype control were conjugated using a DyLight-488 con-
jugation kit (Thermo Scientific, Rockford, Ill). Four-color analysis of the
stained cellswas performedon a FACSCanto II flow cytometer using FACS-
Diva, version 6.0, software (BD Biosciences). All analyses were blinded.
Histologic Examination andMeasurement of Fibrosis
and Luminal Obliteration
The allograft tracheal tissues were fixed, embedded, sectioned, and
stained with hematoxylin and eosin. Allograft trachea sections were photo-
graphed at 43magnification. Collagen depositionwas quantified according
to the percentage of luminal obliteration of the tracheal allografts using Im-
agePro Plus software. Eight allografts were measured in each group.
Collagen Staining and Densitometry
The tracheal sections were deparaffinized, rehydrated, and stained with
Direct Red 80 (Sigma Aldrich, St. Louis, Mo). The images were captured
for quantification using Image J software. The collagen signal in luminal
fibro-obliteration tissue was semiquantified using the same software but
with a different parameter setting.
Statistical Analysis
Fibrocytes from buffy coat, bone marrow, and tracheal single cell sus-
pensions are presented as box and whisker plots. Each box and whisker
plot at a given point represents 5 mice. Continuous data are reported as
either the mean standard deviation or median and interquartile range. In-
dependent sample comparisons were performed using either the Mann-
Whitney U test or Kruskal-Wallis test. Statistical significance was set to
P<.05. Group comparisons were unpaired, and the P values are 2-tailed.
The analyses were performed using predictive analytics software (version
18.0.0; IBM Corp, Chicago, Ill).
RESULTS
Attenuation of Fibrocyte Trafficking Using
Anti-CXCL12 F(ab0)2 Antibody
We first assessed the ability of neutralizing anti-CXCL12
F(ab0)2 antibodies to attenuate fibrocyte trafficking and dif-
ferentiation in the murine model of bronchiolitis obliterans.
Bone marrow, buffy coat, and trachea allograft single-cell
suspensions from Balb/C mice subcutaneously transplanted
with BL6 trachea were analyzed for total undifferentiated
(CD45þCol1þCXCR4þ) and differentiated fibrocyte
(CD45þCol1þa-SMAþ) cell populations.
The comparison of buffy coat isolates from mouse
whole blood preparations revealed significant decrease in
circulating undifferentiated fibrocytes in mice treated withrdiovascular Surgery c Volume 145, Number 3 855
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transplantation. However, anti-CXCL12–treated mice at 12
days after transplantation (Figure 1, A; P ¼ .028) had in-
creased undifferentiated fibrocytes compared with controls.
Figure 1, B shows a concomitant increase in total differen-
tiated fibrocytes in buffy coat preparations from anti-
CXCL12–treated mice at 3 days (P¼ .047), with a decrease
in the differentiated fibrocyte population at 7 days
(P ¼ .008).
Bone marrow aspirates showed an increase in undifferen-
tiated fibrocytes (Figure 1,C) in anti-CXCL12–treated mice
at 12 days after transplantation (P¼ .015) and a decrease in
undifferentiated fibrocytes at 7 days (P¼ .008) and 21 days
(P¼ .014) after transplantation compared with the controls.
Similarly, a significant increase was seen in the number of
total differentiated fibrocytes (Figure 1, D) in the anti-
CXCL12–treated mice at 12 days after transplantation
(P ¼ .004), with a decrease in the same population at 7
days after transplantation (P ¼ .008).
As hypothesized, the single cell suspensions isolated
from the tracheal allografts from anti-CXCL12–treated
mice showed a significant decrease in both undifferentiated
(Figure 1, E) and differentiated (Figure 1, F) fibrocytes at 7
days (P ¼ .009 and P ¼ .009, respectively) and 21 days
(P ¼ .004 and P ¼ .014, respectively) after transplantation
compared with the controls.
The mean ranks of undifferentiated and differentiated fi-
brocytes among buffy coat (H ¼ 18.95, 7 df, P ¼ .008 and
H ¼ 21.92, 7 df, P ¼ .003, respectively), bone marrow
(H ¼ 33.64, 7 df, P < .0001 and H ¼ 34.01, 7 df,
P<.0001, respectively), and tracheal allograft single cell
populations (H ¼ 30.29, 7 df, P<.0001 and H ¼ 33.02, 7
df, P < .0001, respectively) were significantly different
among the control and anti-CXCL12–treated mice. Thus,
a definite variation in fibrocyte number was found within
each group.
Evaluation of Fibro-Obliteration on Tracheal
Allografts
Representative hematoxylin and eosin images of tracheal
allografts from the anti-CXCL12 and control mice at 3, 7,
12, and 21 days after transplantation are shown in
Figure 2. Airway fibro-obliteration was scored using 2
methods. First, qualitative hematoxylin and eosin analysis
was reviewed blindly by a lung pathologist who determined
the percentage of luminal obliteration of tracheal allografts
after tracheal transplantation (Figure 3). A significant de-
crease was seen in the median luminal obliteration at 21
days (P ¼ .010) in the anti-CXCL12–treated mice (65%
vs 100% obliterated in controls; interquartile range, 38%
vs 10%). This trend was not seen at 28 days after transplan-
tation (P ¼ .153).
We next assessed the effect of anti-CXCL12 treatment on
collagen deposition in trachea allograft lumens. Densometric856 The Journal of Thoracic and Cardiovascular Surgquantitative measurement of direct red 80 collagen staining
was used to determine the total luminal collagen deposition
during the same period. As expected, treatment with anti-
CXCL12 resulted in a significant decrease in trachea allograft
luminal collagen deposition at 21 days (1591.62 vs 6314.97
integrated density units; interquartile range, 3167.98 vs
10,725.91; P¼ .042) and 28 days (6871.09 vs 12,775.80 in-
tegrated density units; interquartile range, 5280.35 vs
8346.05; P ¼ .0012) after transplantation (Figure 4). This
is consistent with the hypothesis that inhibition of the
CXCR4/CXCL12 biologic axis results in attenuated fibro-
cyte trafficking to, and differentiation in, tracheal allografts.
The kinetics of total nonluminal tracheal collagen depo-
sition showed a slightly different pattern from that of lumi-
nal deposition (data not shown). A significant decrease in
tracheal fibro-obliteration in the anti-CXCL12–treated
mice at 12 (P<.0001) and 21 (P<.0001) days after trans-
plantation compared with controls, with no significant dif-
ference seen at 3, 7, and 28 days (P>.05).
DISCUSSION
The importance of fibrocyte biology has been established
in multiple pancorporeal fibrotic processes, including nor-
mal wound repair, nephrogenic fibrosing dermatomyop-
athy, scleroderma, chronic pancreatitis, cystitis, liver
fibrosis, and multiple lung pathologies marked by recurring
inflammation and repair.6 We have previously shown a cor-
relation between increased circulating fibrocyte levels and
the development and progression of BOS in patients after
lung transplantation.8 These studies have suggested that fi-
brocytes might contribute to the pathology of pulmonary
fibrosis.
Given the potential clinical importance of fibrocytes in
the progression of fibrotic pathology, we sought to identify
the effect of an anti-CXCL12 F(ab0)2 antibody in mitigating
tracheal fibro-obliteration. Despite its shortcomings, we
used a murine tracheal transplant model of bronchiolitis ob-
literans, because it is well described and less technically de-
manding and time consuming compared with other models
and reproducible in its production of obliterative airway dis-
ease. The critics of this model have noted that this is a large
airway representation of small airway disease and that it
fails to use a vascularized or aerated allograft. Other models
of bronchiolitis obliterans have been developed, including
the orthotopic tracheal model12; however, just as in the het-
erotopic model, this is a large airway model and is not vas-
cularized. Furthermore, it is technically challenging and
fails to uniformly develop histopathologic bronchiolitis ob-
literans. Similarly, single lung transplantation has been suc-
cessfully performed in mice. However, these transplanted
lungs allografts have not been shown to reliably develop
histopathologic lesions of bronchiolitis obliterans.13
In the present study, we have demonstrated that an
anti-CXCL12 antibody effectively attenuates fibrocyteery c March 2013
FIGURE 1. Box and whisker plots depicting total fibrocyte populations in both anti-CXCL12 F(ab0)2–treated and control goat IgG F(ab0)2–treated mice
after heterotopic transplant of allograft tracheas. Box and whiskers represent 25th to 75th and 10th to 90th percentiles, respectively; transverse lines
represent the median. Each box and whisker plot at a given point represents 5 mice. A, C, E, Undifferentiated, CD45þcollagen 1 (Col1)þCXCR4þfibro-
cyte populations over time in buffy coat (BC), bone marrow (BM), and tracheal allograft isolations (Trach), respectively. B, D, F, Differentiated,
CD45þCol1þsmooth muscle actin (SMA)þ fibrocyte populations in BC, bone marrow, and trachea allograft isolations, respectively. *P< .05, Mann-
Whitney U test.
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FIGURE 2. Representative images of hematoxylin and eosin–stained his-
topathologic sections of (left), goat IgG F(ab0)2–treated or (right), anti-
CXCL12 F(ab0)2–treated mice at 3, 7, 12, 21, and 28 days after heterotopic
transplantation of allograft trachea.
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allografts. This antibody simultaneously mitigated graft
disease progression and fibro-obliteration. Our findings
have been corroborated by evidence from other studies
that found that blocking the CXCR4/CXCL12 axis with
an anti-CXCL12 antibody14 or a direct CXCR4 antagonist,
AMD3100,15 protected against pulmonary fibrosis in bleo-
mycin models of IPF—a process defined by cryptogenic
fibro-obliteration of the lung parenchyma.
Recent evidence has pointed toward a duality in fibrocyte
biology as a cell capable of both immune modulation and
extracellular matrix repair.16 The differentiation of fibro-
cytes into cells capable of fulfilling these roles is dependent
on the cytokine milieu and progresses chronologically dur-
ing the disease course from an early role in an inflammatory
phenotype to late differentiation into collagen-producing
reparative cells.17 The results of the present study have
shown a temporal fibrocyte trafficking pattern consistent
with this paradigm in which fibrocytes respond to tracheal
tissue injury by CXCL12 chemotaxis and propagate a tem-
poral fibrotic process. In the acute stages after transplanta-
tion, there is an increase in bone marrow production of both
undifferentiated (CD45þCol1þCXCR4þ) and differentiated
(CD45þCol1þa-SMAþ) fibrocytes in anti-CXCL12–treated
and control mice. As expected, there was a lag in the appear-
ance of both cell populations in buffy coat preparations.
As demonstrated in Figure 5, there is an early accumula-
tion of undifferentiated fibrocytes in tracheal allografts that
might result from the trafficking of fibrocytes already in cir-
culation. However, there is a lack of early concomitant fi-
brosis, suggesting that these fibrocytes are responding to
an inflammatory milieu that exists acutely after transplanta-
tion by differentiating along antigen-presenting or immune-
modulatory cell lines instead of along a reparative cell
lineage. A comparison of control and anti-CXCL12 mice
demonstrated a more rapid and, ultimately, more significant
decrease in fibrocyte numbers in anti-CXCL12–treated
mice and a more rapid and, ultimately, more significant in-
crease in tracheal fibrosis in the control mice. A Kruskal-
Wallis analysis demonstrated that both control and
anti-CXCL12 fibrocyte populations (P<.001) and tracheal
collagen deposition (P<.001) are significantly different.
On closer analysis, the difference between the control
and anti-CXCL12–treated mice was most pronounced at
day 7, when the anti-CXCL12–treated mice have a strik-
ingly decreased number of both fibrocyte populations in
buffy coat and trachea allograft isolations. Although the
control mice continued to experience an increase in fibro-
cyte trafficking and differentiation into grafted airways,
both fibrocyte populations in the anti-CXCL12–treated
mice greatly decreased. Therefore, day 7 might be signifi-
cant in that it represents when the pressure to differentiate
toward an inflammatory lineage subsides and the pressure
to differentiate toward a reparative lineage increases.ery c March 2013
FIGURE 3. Box and whisker plots depicting percentage of luminal fibro-
sis in tracheal allograft sections in both anti-CXCL12 F(ab0)2–treated and
control goat IgG F(ab0)2–treated mice as assessed by a lung pathologist in
a blinded fashion. Box and whiskers represent 25th to 75th and 10th to 90th
percentiles, respectively; transverse lines represent the median. *P<.05,
Mann-Whitney U test.
Harris et al Evolving Technology/Basic ScienceThus, the larger fibrocyte populations on day 7 in the control
mice are able to respond to this pressure and, as a result,
fibro-obliteration occurs more rapidly than in the anti-
CXCL12–treated mice.
Our data have shown that inhibiting the CXCL12/
CXCR4 axis had little effect on the acute bone marrow pro-
duction of fibrocytes but instead appeared more vital in pre-
venting the trafficking of fibrocytes from the bone marrow
into the circulation and from the circulation into the extra-
vascular compartment. Furthermore, the difference in kinet-
ics of collagen deposition between tracheal tissue andFIGURE 4. Box and whisker plots depicting percentage of tracheal lumi-
nal fibrosis as measured using Direct Red 80 collagen stain at 21 and 28
days after transplantation. Box and whiskers represent 25th to 75th and
10th to 90th percentiles, respectively; transverse lines represent the me-
dian. *P<.05, Mann-Whitney U test.
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ing of fibrocytes through the tracheal tissue and into the tra-
cheal lumen. At day 28, no difference was seen in tracheal
tissue collagen deposition between the anti-CXCL12–
treated mice and controls; however, the treated mice
showed a significant decrease in total luminal collagen de-
position, indicating that although the anti-CXCL12 anti-
body did not completely prevent the fibrotic disease from
progressing in the tracheal allograft tissue, it mitigated total
airway obliteration.
The inhibition of CXCL12 could be responsible for the
decreased population of differentiated fibrocytes in the tra-
chea allografts and buffy coat isolations and the decrease in
luminal fibrosis in the anti-CXCL12–treated mice. How-
ever, it is likely that these changes were, in large part, a con-
sequence of diminished trafficking and extravasation of
undifferentiated fibrocytes into the proper milieu for differ-
entiation. Although a drastic decrease was seen in both
buffy coat and tracheal undifferentiated and differentiated
fibrocyte populations in the anti-CXCL12–treated mice,
there was a substantial increase in the same populations in
the control mice. This might suggest that in the control
mice, undifferentiated fibrocytes were more readily able
to traffic to the tracheal allografts and differentiate into fi-
broblastic, collagen-producing cells. Although the differ-
ence in fibrocytes populations might not account for the
entire difference in fibro-obliteration between the anti-
CXCL12–treated and control mice, it does seem to be a ma-
jor contributor to disease progression.
However, we still saw an increasing accumulation of col-
lagen deposition in the tracheal allografts from the anti-
CXCL12–treated mice. This might have been due, in part,
to other less important chemokines (CCR7/CCR2) that
are able to recruit fibrocytes into the allografts. Mouse fibro-
cytes have been shown to express CCR7, CXCR4, and
CCR2 and respond to a number of different ligands.18 The
CXCR4/CXCL12 axis is known to be the predominant re-
ceptor/ligand interaction for trafficking to a grafted airway
and subsequent extravasation of fibrocytes into tissue.5,18,19
These other receptor/ligand interactions might help to
explain the differences in kinetics between the anti-
CXCL12–treated and control groups. Furthermore, local
differentiation of fibroblasts and epithelial to mesenchyme
transition play a role in fibro-obliteration.2 The stimuli for
fibrocyte production in the bone marrow and subsequent
movement to blood is not clear, but it appears that other cy-
tokine/receptor interactions might predominate. Thus,
blocking the CXCR4/CXCL12 axis, although instrumental
for inhibiting the progression of fibro-obliteration, does not,
by itself, eliminate collagen deposition.
Our studies have provided novel insight into the kinetics
of fibrocyte trafficking during the progression of airway
fibro-obliteration and demonstrate the potential that inhibit-
ing this axis has for slowing the disease process.rdiovascular Surgery c Volume 145, Number 3 859
FIGURE 5. Combined kinetics of both undifferentiated, CD45þcollagen 1 (Col1)þCXCR4þfibrocytes in tracheal allografts, as determined by flow cytom-
etry, and tracheal tissue collagen deposition, as determined by Direct Red 80 densitometry of tracheal allograft sections. A, Kinetics of control, goat IgG
F(ab0)2–treated mice showedmore gradual and less complete decrease in tracheal allograft undifferentiated fibrocyte number with a concomitant more rapid
and greater increase in tracheal collagen deposition compared with (B) anti-CXCL12 F(ab0)2–treated mice. Kruskal-Wallis analysis demonstrated that both
control and anti-CXCL12 fibrocyte populations (P<.001) and tracheal collagen deposition (P<.001) were significantly different.
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ing fibrocytes and deterioration of allograft tracheal epithe-
lium and collagen deposition. Thus, the CXCL12/CXCR4
axis provides a novel therapeutic target for the treatment
of fibroproliferative disease. Given the clinical effect that
fibrotic diseases have onmorbidity andmortality, additional
study is warranted in both animal models and humans to
identify the role of this axis in molding fibrocyte differenti-
ation in inflammatory and reparative milieus.
Newer immunomodulatory drugs directed toward inhibi-
tion of the mammalian target of rapamycin (mTOR), such
as sirolimus and everolimus, offer significant hope in the
prevention of allograft rejection.20 Previous studies have860 The Journal of Thoracic and Cardiovascular Surgshown that therapy with rapamycin attenuates fibrocyte
trafficking from bone marrow and prevents fibrocyte and
collagen deposition in lungs challenged with bleomycin
by altering CXCR4 expression.5 Others have shown evero-
limus to be a potent inhibitor of proliferation of ex vivo lung
fibroblasts cultured from transbronchial biopsy samples
harvested from patients after lung transplantation.21 Also,
in 2 separate randomized control trials of lung transplant re-
cipients, those patients receiving maintenance everolimus
were less likely to have clinically suspected and biopsy
proven acute graft rejection compared with the con-
trols.22,23 Because these drugs are currently approved by
the Food and Drug Administration for the prevention ofery c March 2013
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modulation, they might prove to be superior alternatives
to anti-CXCL12 F(ab0)2. Despite this potential, many ther-
apeutic challenges remain to the proper administration of
these drugs. In lung transplant recipients receiving siroli-
mus, an increased risk of severe venous thromboembolism
was present,20 and in separate trials, patients treated with si-
rolimus experienced airway anastomosis dehiscence and
generalized poor wound healing.24,25 Thus, many
clinicians have decided to administer sirolimus after
completion of bronchiolar wound healing,24 and, as such,
the use of sirolimus across all centers was 8% at 1 year
and 18% at 5 years after transplantation.1
CONCLUSIONS
An optimal outcome of mTOR inhibition would allow
mitigation of fibroproliferative disease and, at the same
time, normal wound repair. We suggest that given the inte-
gral nature of mTOR and the CXCR4 biologic axis to the
pathogenesis of fibrosis, monitoring fibrocyte populations
could offer a new biomarker for optimizing mTOR inhibitor
therapy. Quantification of the circulating and lung allograft
fibrocyte populations might provide the clinician with an
individualized view of fibrotic stage/progression in lung
transplant patients. Using these populations as biomarkers,
it might be possible to tailor mTOR inhibitor drug therapy
to a dose that would both maximize gain and minimize un-
wanted side effects on an individual basis, effectively open-
ing the door to a more personalized medical approach for
these patients.
References
1. Christie JD, Edwards LB, Kucheryavaya AY, Benden C, Dobbels F, Kirk R, et al.
The Registry of the International Society for Heart and Lung Transplantation:
Twenty-Eighth Adult Lung and Heart-Lung Transplant Report—2011. J Heart
Lung Transplant. 2011;30:1104-22.
2. Strieter RM, Mehrad B. New mechanisms of pulmonary fibrosis. Chest. 2009;
136:1364-70.
3. Strieter RM, Keeley EC, Burdick MD, Mehrad B. The role of circulating mesen-
chymal progenitor cells, fibrocytes, in promoting pulmonary fibrosis. Trans Am
Clin Climatol Assoc. 2009;120:49-59.
4. Strieter RM, Gomperts BN, Keane MP. The role of CXC chemokines in pulmo-
nary fibrosis. J Clin Invest. 2007;117:549-56.
5. Mehrad B, BurdickMD, Strieter RM. Fibrocyte CXCR4 regulation as a therapeu-
tic target in pulmonary fibrosis. Int J Biochem Cell Biol. 2009;41:1708-18.
6. Herzog EL, Bucala R. Fibrocytes in health and disease. Exp Hematol. 2010;38:
548-56.The Journal of Thoracic and Ca7. Moeller A, Gilpin SE, Ask K, Cox G, Cook D, Gauldie J, et al. Circulating fibro-
cytes are an indicator of poor prognosis in idiopathic pulmonary fibrosis. Am J
Respir Crit Care Med. 2009;179:588-94.
8. Lapar DJ, Burdick MD, Emaminia A, Harris DA, Strieter BA, Liu L, et al. Cir-
culating fibrocytes correlate with bronchiolitis obliterans syndrome development
after lung transplantation: a novel clinical biomarker. Ann Thorac Surg. 2011;92:
470-7.
9. Andersson-Sj€oland A, Erjef€alt JS, Bjermer L, Eriksson L, Westergren-
Thorsson G. Fibrocytes are associated with vascular and parenchymal remodel-
ling in patients with obliterative bronchiolitis. Respir Res. 2009;10:103.
10. Zhao Y, Lapar DJ, Steidle J, Emaminia A, Kron IL, Ailawadi G, et al. Adenosine
signaling via the adenosine 2B receptor is involved in bronchiolitis obliterans de-
velopment. J Heart Lung Transplant. 2010;29:1405-14.
11. Lau CL, Zhao Y, Kron IL, Stoler MH, Laubach VE, Ailawadi G, et al. The role of
adenosine A2A receptor signaling in bronchiolitis obliterans. Ann Thorac Surg.
2009;88:1071-8.
12. Okazaki M, Krupnick AS, Kornfeld CG, Lai JM, Ritter JH, Richardson SB, et al.
A mouse model of orthotopic vascularized aerated lung transplantation. Am J
Transplant. 2007;7:1672-9.
13. Hele DJ, Yacoub MH, Belvisi MG. The heterotopic tracheal allograft as an ani-
mal model of obliterative bronchiolitis. Respir Res. 2001;2:169-83.
14. Phillips RJ, Burdick MD, Hong K, Lutz MA, Murray LA, Xue YY, et al. Circu-
lating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis.
J Clin Invest. 2004;114:438-46.
15. Song JS, Kang CM, Kang HH, Yoon HK, Kim YK, Kim KH, et al. Inhibitory ef-
fect of CXC chemokine receptor 4 antagonist AMD3100 on bleomycin induced
murine pulmonary fibrosis. Exp Mol Med. 2010;42:465-72.
16. Balmelli C, AlvesMP, Steiner E, Zingg D, Peduto N, Ruggli N, et al. Responsive-
ness of fibrocytes to toll-like receptor danger signals. Immunobiology. 2007;212:
693-9.
17. Reilkoff RA, Bucala R, Herzog EL. Fibrocytes: emerging effector cells in
chronic inflammation. Nat Rev Immunol. 2011;11:427-35.
18. Gomperts BN, Strieter RM. Fibrocytes in lung disease. J Leukoc Biol. 2007;82:
449-56.
19. Xu J, Mora A, Shim H, Stecenko A, Brigham KL, Rojas M. Role of the SDF-1/
CXCR4 axis in the pathogenesis of lung injury and fibrosis. Am J Respir Cell Mol
Biol. 2007;37:291-9.
20. Ahya VN, McShane PJ, Baz MA, Valentine VG, Arcasoy SM, Love RB, et al.
Increased risk of venous thromboembolism with a sirolimus-based immunosup-
pression regimen in lung transplantation. J Heart Lung Transplant. 2011;30:
175-81.
21. Azzola A, Havryk A, Chhajed P, Hostettler K, Black J, Johnson P, et al. Evero-
limus and mycophenolate mofetil are potent inhibitors of fibroblast proliferation
after lung transplantation. Transplantation. 2004;77:275-80.
22. Kovarik JM, Snell GI, Valentine V, Aris R, Chan CKN, Schmidli H, et al. Ever-
olimus in pulmonary transplantation: pharmacokinetics and exposure–response
relationships. J Heart Lung Transplant. 2006;25:440-6.
23. Snell GI, Valentine VG, Vitulo P, Glanville AR, McGiffin DC, Loyd JE, et al.
Everolimus versus azathioprine in maintenance lung transplant recipients: an in-
ternational, randomized, double-blind clinical trial. Am J Transplant. 2006;6:
169-77.
24. Groetzner J, Kur F, Spelsberg F, Behr J, Frey L, Bittmann I, et al. Airway anas-
tomosis complications in de novo lung transplantation with sirolimus-based im-
munosuppression. J Heart Lung Transplant. 2004;23:632-8.
25. King-Biggs MB, Dunitz JM, Park SJ, Kay Savik S, Hertz MI. Airway anasto-
motic dehiscence associated with use of sirolimus immediately after lung trans-
plantation. Transplantation. 2003;75:1437-43.rdiovascular Surgery c Volume 145, Number 3 861
